1 0

    FDA ANDA Approval Routing Sheets & Letters for Viibryd – Teva (ANDA 208212), Invagen (ANDA 208200), Alembic (ANDA 208202), Accrod (ANDA 208209)

    FDA ANDA Approval Routing Sheets & Letters for Viibryd – Teva (ANDA 208212), Invagen (ANDA 208200), Alembic (ANDA 208202), Accrod (ANDA 208209)

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request Contents: Approval routing sheets and approval letters for Viibryd (vilazodone HCl) ANDAs: Teva (ANDA 208212, approved 9/30/2019), Invagen (ANDA 208200, approved 4/7/2021 & 12/6/2022), Alembic (ANDA 208202, approved 1/10/2020), Accrod (ANDA 208209, approved 4/27/2021)
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details